Prodrug-based Nanomedicines for Rheumatoid Arthritis

Overview

Journal Discov Nano

Date 2024 Jan 5

PMID 38180534

Authors

Pei Li

Cong Wang

Hongjie Huo

Chunyun Xu

Huijun Sun

Xinyu Wang

Li Wang

Lei Li

Affiliations

Soon will be listed here.

Abstract

Most antirheumatic drugs with high toxicity exhibit a narrow therapeutic window due to their nonspecific distribution in the body, leading to undesirable side effects and reduced patient compliance. To in response to these challenges, prodrug-based nanoparticulate drug delivery systems (PNDDS), which combines prodrug strategy and nanotechnology into a single system, resulting their many advantages, including stability for prodrug structure, the higher drug loading capacity of the system, improving the target activity and bioavailability, and reducing their untoward effects. PNDDS have gained attention as a method for relieving arthralgia syndrome of rheumatoid arthritis in recent years. This article systematically reviews prodrug-based nanocarriers for rheumatism treatment, including Nano systems based on prodrug-encapsulated nanomedicines and conjugate-based nanomedicines. It provides a new direction for the clinical treatment of rheumatoid arthritis.

References

Tee J, Yip L, Tan E, Santitewagun S, Prasath A, Ke P . Nanoparticles' interactions with vasculature in diseases. Chem Soc Rev. 2019; 48(21):5381-5407. DOI: 10.1039/c9cs00309f. View

Li Q, Zhou W, Wang Y, Kou F, Lyu C, Wei H . Metabolic mechanism and anti-inflammation effects of sinomenine and its major metabolites N-demethylsinomenine and sinomenine-N-oxide. Life Sci. 2020; 261:118433. DOI: 10.1016/j.lfs.2020.118433. View

Dahl L, Dahl I, Engstrom-Laurent A, Granath K . Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985; 44(12):817-22. PMC: 1001790. DOI: 10.1136/ard.44.12.817. View

Al-Lawati H, Vakili M, Lavasanifar A, Ahmed S, Jamali F . Reduced Heart Exposure of Diclofenac by Its Polymeric Micellar Formulation Normalizes CYP-Mediated Metabolism of Arachidonic Acid Imbalance in An Adjuvant Arthritis Rat Model: Implications in Reduced Cardiovascular Side Effects of Diclofenac by.... Mol Pharm. 2020; 17(4):1377-1386. DOI: 10.1021/acs.molpharmaceut.0c00069. View

Graversen J, Svendsen P, Dagnaes-Hansen F, Dal J, Anton G, Etzerodt A . Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther. 2012; 20(8):1550-8. PMC: 3412497. DOI: 10.1038/mt.2012.103. View

Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad O . Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2013; 66:2-25. PMC: 4219254. DOI: 10.1016/j.addr.2013.11.009. View

Van S, Das S, Wang X, Feng Z, Jin Y, Hou Z . Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. Int J Nanomedicine. 2010; 5:825-37. PMC: 2964040. DOI: 10.2147/IJN.S13482. View

Ma S, Gu S, Zhang J, Qi W, Lin Z, Zhai W . Robust drug bioavailability and safety for rheumatoid arthritis therapy using D-amino acids-based supramolecular hydrogels. Mater Today Bio. 2022; 15:100296. PMC: 9157599. DOI: 10.1016/j.mtbio.2022.100296. View

Wang Q, Sun X . Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci. 2017; 5(8):1407-1420. DOI: 10.1039/c7bm00254h. View

10.

Quan L, Zhang Y, Crielaard B, Dusad A, Lele S, Rijcken C . Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano. 2013; 8(1):458-466. PMC: 3947749. DOI: 10.1021/nn4048205. View

11.

Li Y, Wei S, Sun Y, Zong S, Sui Y . Nanomedicine-based combination of dexamethasone palmitate and MCL-1 siRNA for synergistic therapeutic efficacy against rheumatoid arthritis. Drug Deliv Transl Res. 2021; 11(6):2520-2529. DOI: 10.1007/s13346-021-01037-x. View

12.

Huttunen K, Raunio H, Rautio J . Prodrugs--from serendipity to rational design. Pharmacol Rev. 2011; 63(3):750-71. DOI: 10.1124/pr.110.003459. View

13.

Metselaar J, Wauben M, Wagenaar-Hilbers J, Boerman O, Storm G . Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 2003; 48(7):2059-66. DOI: 10.1002/art.11140. View

14.

GARRETT E, EBLE T . Studies on the stability of fumagillin. I. Photolytic degradation in alcohol solution. J Am Pharm Assoc Am Pharm Assoc. 1954; 43(7):385-90. DOI: 10.1002/jps.3030430702. View

15.

CUMMINGS N, NORDBY G . Measurement of synovial fluid pH in normal and arthritic knees. Arthritis Rheum. 1966; 9(1):47-56. DOI: 10.1002/art.1780090106. View

16.

Jung Y, Park W, Na K . Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis. J Control Release. 2013; 171(2):143-51. DOI: 10.1016/j.jconrel.2013.07.012. View

17.

Timofeevski S, Panarin E, Vinogradov O, Nezhentsev M . Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Pharm Res. 1996; 13(3):476-80. DOI: 10.1023/a:1016069315423. View

18.

Buckley C, Ospelt C, Gay S, Midwood K . Location, location, location: how the tissue microenvironment affects inflammation in RA. Nat Rev Rheumatol. 2021; 17(4):195-212. DOI: 10.1038/s41584-020-00570-2. View

19.

Maassen J, van Ouwerkerk L, Allaart C . Tapering of disease-modifying antirheumatic drugs: an overview for daily practice. Lancet Rheumatol. 2024; 3(9):e659-e670. DOI: 10.1016/S2665-9913(21)00224-1. View

20.

Ebbesen M, Bienk K, Deleuran B, Howard K . Extended blood circulation and joint accumulation of a p(HPMA-co-AzMA)-based nanoconjugate in a murine model of rheumatoid arthritis. Mol Cell Ther. 2015; 2:29. PMC: 4452064. View